

Supplementary Materials

Table S1. Primer sequences.

	Forward primer (5'-3')	Reverse primer (5'-3')	Probe (5'-3')
RT-qPCR primers			
vtRNA1-1	TGGCTTAGCTCAGCGGTTAC	TCTCGAACAAACCCAGACAGGTT	TCGACAGTTCTTAATTGA
vtRNA1-2	TGGCTTAGCTCAGCGGTTAC	GGTCTCGAACCAACCCAGAGA	TCGAGTACATTGTAACCAC
vtRNA1-3	TGGCTTAGCTCAGCGGTTAC	GGGTCTCGAACAAACCCAGAGA	CGTGTCAATCAAACCAC
GAPDH	agggtggctccctgactcaacag	Gaaatgagcttgcacaagtggcgt	NA
Bisulfite sequencing primers			
vtRNA1-1	AAGAGTTTTAGGGATTAGGAA AGGT	CAACCCAAACAAATTACTTATTCAATTAAAAACTA	NA
vtRNA1-2	TTTGGTTAAGTATTAGTTGAAA AGT	TCCTCTCAACAATCACCTA	NA
vtRNA1-3	AGTTGTGGATTAGGTGATTGTT	CTAAACTAAAACCAACCCAAAAATT	NA
Ms-SNuPE primers			
vtRNA1-1	AAGAGTTTTAGGGATTAGGAA AGGT	CAACCCAAACAAATTACTTATTCAATTAAAAACTA	AGGGATTAGGAAAGGTTA ATAATTTTTAATTGTTGGAGGT AGGTTTTTTATTAGTTAATAAAATATAATT
vtRNA1-2	TTTGGTTAAGTATTAGTTGAAA AGT	TCCTCTCAACAATCACCTA	TTGTTGTTGGAG GAAAATAAGTTAGGTATATAATTG GTATATTAAATTGTTGGAGG GAGGAGAGAATAAAT
vtRNA1-3	AGTTGTGGATTAGGTGATTGTT	CTAAACTAAAACCAACCCAAAAATT	GATTGGATAGTTAGGT TTGTTTGATTATTTTGTA
Pyrosequencing primers			
vtRNA1-3 outer	TGTATGTTTAGATGGATATT	AACATTACTAACACTAAAAAACTT	NA
vtRNA1-3 nested	TGTATGTTTAGATGGATATT	AAAACCAACCCAAAAATTACTTT	NA




Figure S1. Re-activation of *VTRNA1-3* correlates with increased H3K4me3. HL60 cells were treated for 24 h with 5-Aza-CdR and harvested on D2 and ChIP against IgG and H3K4me3 was performed at (A) *VTRNA1-1* promoter (left panel) and TSS (right panel); and (B) *VTRNA1-3* promoter (left panel) and TSS (right panel). As *VTRNA1-1* is unmethylated, active in controls and unaffected by 5-Aza-CdR, we expect no change in H3K4me3. Significant differences are indicated by * (student's *t*-test). Mean + SD shown.




Figure S2. Methylation of the *VTRNA1-3* promoter in healthy donors. The mean methylation levels determined by pyrosequencing in individual donor's MNCs from blood or bone marrow are shown. We collected both blood and bone marrow MNCs from 7 of the 20 healthy donors used in this study. As the *VTRNA1-3* promoter methylation levels for blood and bone marrow MNCs are identical within the individual donors, the mean methylation was calculated from the blood MNCs methylation values. The cutoff was defined as mean *VTRNA1-3* methylation + 2*SD = $\geq 20\%$.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).